Kitler M E
Associates in Business and Research, Gilly, Switzerland.
Drug Saf. 1994 Nov;11(5):378-91. doi: 10.2165/00002018-199411050-00005.
It is generally agreed that the advance of a global economy must be accompanied by global drug development. Thus, more intense effort, time and expense must be given to the study of overall global population, which will ultimately be exposed to the drug in development. Race and ethnicity of the ultimate drug consumer must be evaluated, and not only in broad terms. Ethnic and racial representations must be considered in clinical trials. The differences in response to drug action in various ethnic and racial groups must be evaluated to provide information for the physician in practice, who is faced with an increasingly nonhomogeneous population, and who must prescribe medications for those patients. The practising physician urgently requires international, crosscultural collaborative studies, using standardised methods applicable to different cultural settings.
人们普遍认为，全球经济的发展必须伴随着全球药物研发。因此，必须投入更多的精力、时间和费用来研究最终会接触到正在研发药物的全球总体人群。必须评估最终药物消费者的种族和民族，而且不能仅从宽泛的角度进行评估。在临床试验中必须考虑种族和民族代表性。必须评估不同种族和民族群体对药物作用的反应差异，以便为在实际工作中面对日益多样化人群且必须为这些患者开处方的医生提供信息。执业医生迫切需要开展国际跨文化合作研究，采用适用于不同文化背景的标准化方法。
